Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.

Sci Rep · 2022 · PMC9399082 · PMID 35999229

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

19 reported nominally significant improvement in many EORTC-QLQC30 symptom domains with pembrolizumab, and nominally significant worsening with docetaxel.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.